We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+5.41%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$40.2B
AUM Growth
+$172M
(+0.43%)
Cap. Flow
-$1.31B
Cap. Flow
% of AUM
-3.26%
Top 10 Holdings %
Top 10 Hldgs %
18.88%
Holding
794
New
108
Increased
186
Reduced
363
Closed
91
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$427M |
| 2 |
RTN
Raytheon Company
RTN
|
+$193M |
| 3 |
RTX Corp
RTX
|
+$181M |
| 4 |
Marathon Petroleum
MPC
|
+$163M |
| 5 |
Deere & Co
DE
|
+$137M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Honeywell
HON
|
+$263M |
| 2 |
DuPont de Nemours
DD
|
+$238M |
| 3 |
Walmart Inc
WMT
|
+$216M |
| 4 |
Ross Stores
ROST
|
+$195M |
| 5 |
Fortive
FTV
|
+$129M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.26% |
| 2 | Technology | 15.21% |
| 3 | Financials | 12.82% |
| 4 | Consumer Discretionary | 11.4% |
| 5 | Industrials | 10.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PRVL
551
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
| $8.39M | 0.02% |
+635,327
| New | +$9.26M |
|
552
Everest Group
EG
$14.9B
| $8.35M | 0.02% |
33,799
-16,600
| -33% | -$3.98M |
|
553
DaVita
DVA
$15.3B
| $8.28M | 0.02% |
147,250
+92,100
| +167% | +$4.77M |
|
|
TPTX
554
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $8.14M | 0.02% |
+200,000
| New | +$7.13M |
|
555
A.O. Smith
AOS
$8.24B
| $8.1M | 0.02% |
+171,720
| New | +$8.42M |
|
556
Liberty Energy
LBRT
$2.93B
| $8.09M | 0.02% |
500,000
| – | – |
|
|
UROV
557
DELISTED
Urovant Sciences Ltd.
UROV
| $7.91M | 0.02% |
1,000,000
-385,000
| -28% | -$3.16M |
|
558
Globe Life
GL
$14.2B
| $7.91M | 0.02% |
+88,400
| New | +$7.71M |
|
559
Halozyme
HALO
$9.88B
| $7.73M | 0.02% |
450,000
+300,000
| +200% | +$4.84M |
|
|
HBI
560
DELISTED
Hanesbrands
HBI
| $7.62M | 0.02% |
442,350
+110
| +0% | +$1.9K |
|
561
Kilroy Realty
KRC
$4.6B
| $7.47M | 0.02% |
101,254
-14,692
| -13% | -$1.12M |
|
562
STMicroelectronics
STM
$47.3B
| $7.43M | 0.02% |
+421,800
| New | +$7.13M |
|
563
Ironwood Pharmaceuticals
IRWD
$614M
| $7.38M | 0.02% |
675,000
-1,563,750
| -70% | -$17.5M |
|
564
Indaptus Therapeutics
INDP
$192M
| $7.38M | 0.02% |
759
| – | – |
|
565
Truist Financial
TFC
$63.5B
| $7.36M | 0.02% |
+149,800
| New | +$7.34M |
|
|
SILK
566
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $7.29M | 0.02% |
+150,500
| New | +$6.4M |
|
|
FPRX
567
DELISTED
Five Prime Therapeutics, Inc.
FPRX
| $7.24M | 0.02% |
1,200,000
+50,000
| +4% | +$478K |
|
568
Fortinet
FTNT
$113B
| $7.19M | 0.02% |
468,090
-420,500
| -47% | -$6.92M |
|
569
Arrow Electronics
ARW
$10.9B
| $7.15M | 0.02% |
100,385
-262,384
| -72% | -$19.3M |
|
570
Newell Brands
NWL
$2.18B
| $7.13M | 0.02% |
462,600
-24,400
| -5% | -$365K |
|
571
Northrop Grumman
NOC
$76B
| $7.13M | 0.02% |
22,057
-211,134
| -91% | -$62.9M |
|
572
Bread Financial
BFH
$4.47B
| $7.06M | 0.02% |
63,162
-8,382
| -12% | -$1.01M |
|
573
Aldeyra Therapeutics
ALDX
$96.5M
| $7.01M | 0.02% |
1,168,822
+50,000
| +4% | +$376K |
|
574
H&R Block
HRB
$5.61B
| $6.97M | 0.02% |
237,800
-12,800
| -5% | -$344K |
|
575
Pentair
PNR
$10.6B
| $6.9M | 0.02% |
+185,597
| New | +$7.04M |
|
Similar funds
Adage Capital Partners's Q2 2019 Portfolio in Review
As of Q2 2019, Adage Capital Partners held 794 positions worth $40.2B, up 0.43% from $40B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Adage Capital Partners withdrew a net $1.31B in Q2 2019, closing 91 positions and reducing 363 holdings. Its most notable exit was InflaRx, an estimated $85.9M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
Against the trend, Adage Capital Partners opened a new position in Raytheon Company worth $186M.
- Adage Capital Partners's largest Q2 2019 buy was Raytheon Company: 1,071,108 shares worth $186M.
- Adage Capital Partners added most to Celgene Corp in Q2 2019, an estimated $427M increase.
- Adage Capital Partners's biggest Q2 2019 reduction was Honeywell, cutting an estimated $263M.
- Adage Capital Partners fully exited InflaRx in Q2 2019, selling an estimated $85.9M.
- Adage Capital Partners's ten largest holdings make up 19% of its $40.2B portfolio in Q2 2019.
- Adage Capital Partners opened 108 new positions and closed 91 in Q2 2019.
- Adage Capital Partners's portfolio value rose 0.43% quarter-over-quarter to $40.2B.
Based on Adage Capital Partners's 13F filing for Q2 2019, filed 14 Aug 2019.